| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracorporeal Membrane Oxygenation | 16 | 2024 | 621 | 3.940 |
Why?
|
| Heparin | 16 | 2023 | 227 | 2.840 |
Why?
|
| Anticoagulants | 19 | 2024 | 581 | 2.580 |
Why?
|
| Thrombosis | 12 | 2023 | 520 | 2.540 |
Why?
|
| Hemorrhage | 11 | 2022 | 459 | 2.340 |
Why?
|
| Blood Coagulation | 12 | 2023 | 118 | 2.120 |
Why?
|
| Antithrombins | 7 | 2024 | 56 | 1.970 |
Why?
|
| Thrombelastography | 7 | 2021 | 55 | 1.880 |
Why?
|
| Partial Thromboplastin Time | 7 | 2021 | 45 | 1.790 |
Why?
|
| Hemostasis | 8 | 2024 | 69 | 1.760 |
Why?
|
| Heart-Assist Devices | 11 | 2024 | 1026 | 1.630 |
Why?
|
| Blood Coagulation Disorders | 7 | 2021 | 100 | 1.580 |
Why?
|
| Hirudins | 5 | 2024 | 37 | 1.410 |
Why?
|
| Hemostatics | 4 | 2021 | 57 | 1.260 |
Why?
|
| Blood Coagulation Tests | 9 | 2021 | 60 | 1.250 |
Why?
|
| Drug Monitoring | 5 | 2020 | 157 | 1.230 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2020 | 343 | 1.190 |
Why?
|
| von Willebrand Diseases | 4 | 2019 | 50 | 1.170 |
Why?
|
| Erythrocyte Transfusion | 6 | 2020 | 122 | 1.060 |
Why?
|
| Factor VIII | 4 | 2020 | 44 | 1.050 |
Why?
|
| Peptide Fragments | 6 | 2024 | 747 | 1.040 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2015 | 54 | 1.030 |
Why?
|
| ADAM Proteins | 3 | 2015 | 79 | 1.010 |
Why?
|
| Thrombophilia | 3 | 2022 | 40 | 0.930 |
Why?
|
| Citrates | 1 | 2024 | 22 | 0.900 |
Why?
|
| Citric Acid | 1 | 2024 | 35 | 0.890 |
Why?
|
| Plasma | 3 | 2020 | 96 | 0.880 |
Why?
|
| Factor Xa | 3 | 2017 | 17 | 0.860 |
Why?
|
| Blood Transfusion | 4 | 2022 | 301 | 0.810 |
Why?
|
| Fetal Blood | 3 | 2016 | 177 | 0.800 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2023 | 1099 | 0.800 |
Why?
|
| Factor V | 3 | 2022 | 17 | 0.780 |
Why?
|
| Humans | 91 | 2024 | 123223 | 0.760 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 29 | 0.730 |
Why?
|
| Fibrinogen | 6 | 2024 | 151 | 0.700 |
Why?
|
| Child | 41 | 2024 | 24240 | 0.700 |
Why?
|
| Infant, Newborn | 18 | 2024 | 8108 | 0.660 |
Why?
|
| Blood Platelets | 7 | 2020 | 333 | 0.630 |
Why?
|
| Placenta Accreta | 5 | 2019 | 144 | 0.630 |
Why?
|
| Hemoglobins | 3 | 2015 | 301 | 0.620 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 406 | 0.590 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2014 | 35 | 0.590 |
Why?
|
| Menorrhagia | 3 | 2013 | 74 | 0.580 |
Why?
|
| Whole Blood Coagulation Time | 3 | 2014 | 12 | 0.570 |
Why?
|
| Recombinant Proteins | 5 | 2023 | 1386 | 0.570 |
Why?
|
| Vitamin K Deficiency | 1 | 2016 | 3 | 0.540 |
Why?
|
| International Normalized Ratio | 1 | 2016 | 42 | 0.530 |
Why?
|
| Vitamin K | 1 | 2016 | 35 | 0.520 |
Why?
|
| Warfarin | 3 | 2012 | 118 | 0.520 |
Why?
|
| Child, Preschool | 27 | 2024 | 13888 | 0.510 |
Why?
|
| Protein Precursors | 1 | 2016 | 149 | 0.500 |
Why?
|
| Infant | 22 | 2024 | 12349 | 0.500 |
Why?
|
| Retrospective Studies | 29 | 2023 | 16033 | 0.500 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 228 | 0.490 |
Why?
|
| Female | 49 | 2024 | 65549 | 0.480 |
Why?
|
| Heart Defects, Congenital | 3 | 2023 | 1806 | 0.480 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 167 | 0.470 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 100 | 0.470 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2014 | 4 | 0.470 |
Why?
|
| Fibrinolysin | 1 | 2014 | 10 | 0.470 |
Why?
|
| Hysterectomy | 5 | 2019 | 185 | 0.460 |
Why?
|
| Health Information Systems | 1 | 2014 | 32 | 0.450 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 64 | 0.450 |
Why?
|
| Bilirubin | 1 | 2014 | 121 | 0.450 |
Why?
|
| Plasma Exchange | 3 | 2018 | 83 | 0.440 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2013 | 11 | 0.440 |
Why?
|
| Blood Banks | 2 | 2015 | 12 | 0.430 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 141 | 0.430 |
Why?
|
| von Willebrand Factor | 5 | 2024 | 197 | 0.420 |
Why?
|
| Platelet Function Tests | 5 | 2015 | 38 | 0.410 |
Why?
|
| beta-Alanine | 1 | 2012 | 8 | 0.410 |
Why?
|
| Blood Platelet Disorders | 1 | 2012 | 13 | 0.410 |
Why?
|
| Blood Loss, Surgical | 5 | 2019 | 146 | 0.400 |
Why?
|
| Riots | 1 | 2012 | 2 | 0.400 |
Why?
|
| Blood Safety | 1 | 2012 | 4 | 0.400 |
Why?
|
| Adolescent | 24 | 2023 | 19110 | 0.390 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 255 | 0.380 |
Why?
|
| Benzimidazoles | 1 | 2012 | 129 | 0.380 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2010 | 2 | 0.350 |
Why?
|
| Preoperative Care | 1 | 2012 | 350 | 0.340 |
Why?
|
| Disseminated Intravascular Coagulation | 3 | 2022 | 67 | 0.340 |
Why?
|
| Thrombin | 1 | 2010 | 60 | 0.340 |
Why?
|
| Male | 34 | 2024 | 60117 | 0.340 |
Why?
|
| Biomarkers | 2 | 2016 | 2946 | 0.340 |
Why?
|
| Databases, Factual | 1 | 2014 | 1168 | 0.330 |
Why?
|
| Prothrombin Time | 4 | 2016 | 36 | 0.310 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 365 | 0.310 |
Why?
|
| Platelet Transfusion | 3 | 2019 | 53 | 0.310 |
Why?
|
| Blood Component Removal | 2 | 2012 | 32 | 0.300 |
Why?
|
| Prospective Studies | 8 | 2024 | 6040 | 0.300 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 7 | 0.290 |
Why?
|
| Adult | 18 | 2024 | 29072 | 0.290 |
Why?
|
| Enoxaparin | 2 | 2017 | 42 | 0.290 |
Why?
|
| Fibrinolytic Agents | 2 | 2020 | 198 | 0.280 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2007 | 143 | 0.280 |
Why?
|
| Serologic Tests | 1 | 2007 | 117 | 0.280 |
Why?
|
| Stroke | 3 | 2023 | 958 | 0.280 |
Why?
|
| Heart Transplantation | 2 | 2023 | 854 | 0.270 |
Why?
|
| Aspirin | 2 | 2008 | 224 | 0.260 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 257 | 0.260 |
Why?
|
| Antithrombin III | 2 | 2017 | 25 | 0.260 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2112 | 0.260 |
Why?
|
| Heart Failure | 3 | 2023 | 2127 | 0.260 |
Why?
|
| Anemia, Sickle Cell | 2 | 2011 | 334 | 0.260 |
Why?
|
| Immunologic Factors | 1 | 2007 | 179 | 0.260 |
Why?
|
| Prothrombin | 2 | 2016 | 24 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1262 | 0.250 |
Why?
|
| Age Factors | 6 | 2018 | 2802 | 0.250 |
Why?
|
| Hypersensitivity | 2 | 2021 | 182 | 0.240 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 27 | 0.240 |
Why?
|
| Pregnancy | 9 | 2022 | 7161 | 0.240 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2003 | 6 | 0.230 |
Why?
|
| Protein S | 2 | 2016 | 10 | 0.230 |
Why?
|
| Protein C | 2 | 2016 | 21 | 0.230 |
Why?
|
| Young Adult | 8 | 2023 | 8865 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2023 | 12141 | 0.220 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 65 | 0.210 |
Why?
|
| Activated Protein C Resistance | 1 | 2022 | 2 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 117 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 202 | 0.210 |
Why?
|
| Egypt | 2 | 2013 | 23 | 0.210 |
Why?
|
| Time Factors | 6 | 2022 | 6221 | 0.210 |
Why?
|
| Fibrinolysis | 2 | 2014 | 38 | 0.210 |
Why?
|
| Protein C Deficiency | 1 | 2022 | 12 | 0.200 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2013 | 18 | 0.200 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 77 | 0.200 |
Why?
|
| Isoantibodies | 2 | 2013 | 70 | 0.200 |
Why?
|
| Referral and Consultation | 1 | 2005 | 529 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2022 | 118 | 0.190 |
Why?
|
| Afibrinogenemia | 1 | 2021 | 10 | 0.190 |
Why?
|
| Critical Illness | 2 | 2024 | 591 | 0.190 |
Why?
|
| Cesarean Section | 4 | 2019 | 385 | 0.180 |
Why?
|
| Pregnancy Trimesters | 1 | 2021 | 33 | 0.180 |
Why?
|
| Postpartum Hemorrhage | 2 | 2019 | 91 | 0.180 |
Why?
|
| Heparitin Sulfate | 1 | 2020 | 20 | 0.180 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 12 | 0.180 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 133 | 0.170 |
Why?
|
| Coagulants | 1 | 2019 | 7 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2021 | 79 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 207 | 0.170 |
Why?
|
| Liver Failure | 1 | 2020 | 89 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2019 | 36 | 0.160 |
Why?
|
| Factor IX | 3 | 2023 | 15 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 770 | 0.160 |
Why?
|
| Blood Coagulation Factors | 2 | 2023 | 34 | 0.160 |
Why?
|
| Materials Testing | 1 | 2018 | 73 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 1198 | 0.150 |
Why?
|
| Exercise | 1 | 2024 | 808 | 0.150 |
Why?
|
| Models, Biological | 3 | 2017 | 1441 | 0.150 |
Why?
|
| Surface Properties | 1 | 2018 | 76 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 120 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2019 | 470 | 0.150 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 52 | 0.150 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 391 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 3378 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 143 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2018 | 235 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2017 | 84 | 0.140 |
Why?
|
| Syndrome | 1 | 2019 | 1115 | 0.140 |
Why?
|
| ADAMTS13 Protein | 2 | 2014 | 62 | 0.130 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 19 | 0.130 |
Why?
|
| Staphylococcus aureus | 2 | 2012 | 456 | 0.130 |
Why?
|
| Pediatrics | 1 | 2005 | 1141 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 134 | 0.130 |
Why?
|
| Blood Donors | 2 | 2015 | 62 | 0.130 |
Why?
|
| Inventories, Hospital | 1 | 2015 | 1 | 0.130 |
Why?
|
| Drug Resistance | 2 | 2008 | 256 | 0.130 |
Why?
|
| Platelet Adhesiveness | 1 | 2015 | 40 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1135 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 481 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 494 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2015 | 29 | 0.120 |
Why?
|
| Term Birth | 1 | 2015 | 33 | 0.120 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 28 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1682 | 0.120 |
Why?
|
| Pipecolic Acids | 1 | 2014 | 6 | 0.120 |
Why?
|
| Placenta, Retained | 1 | 2014 | 11 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1014 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 553 | 0.120 |
Why?
|
| Thromboxane B2 | 1 | 2014 | 20 | 0.120 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 131 | 0.120 |
Why?
|
| Cattle | 2 | 2018 | 558 | 0.120 |
Why?
|
| Leukocyte Transfusion | 1 | 2014 | 5 | 0.110 |
Why?
|
| Nutritional Status | 1 | 2016 | 304 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 478 | 0.110 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 63 | 0.110 |
Why?
|
| Granulocytes | 1 | 2014 | 65 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2023 | 3014 | 0.110 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2013 | 8 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2015 | 356 | 0.100 |
Why?
|
| Food-Drug Interactions | 1 | 2012 | 10 | 0.100 |
Why?
|
| Subcutaneous Tissue | 1 | 2012 | 15 | 0.100 |
Why?
|
| Arginine | 1 | 2014 | 303 | 0.100 |
Why?
|
| Dabigatran | 1 | 2012 | 26 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 259 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 36 | 0.100 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 23 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 126 | 0.100 |
Why?
|
| Neutropenia | 1 | 2014 | 202 | 0.100 |
Why?
|
| Necrosis | 1 | 2012 | 205 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 120 | 0.100 |
Why?
|
| Hospitals, Urban | 1 | 2012 | 97 | 0.100 |
Why?
|
| Reference Values | 2 | 2015 | 697 | 0.100 |
Why?
|
| Laboratories | 1 | 2012 | 83 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2012 | 143 | 0.090 |
Why?
|
| Outpatients | 2 | 2022 | 253 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2012 | 114 | 0.090 |
Why?
|
| Syphilis | 1 | 2012 | 95 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2015 | 845 | 0.090 |
Why?
|
| Heparin Lyase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2012 | 123 | 0.090 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2010 | 11 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 175 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 178 | 0.090 |
Why?
|
| Coinfection | 1 | 2012 | 176 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 159 | 0.090 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2010 | 99 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 356 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2012 | 670 | 0.090 |
Why?
|
| Incidence | 2 | 2015 | 3048 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 715 | 0.090 |
Why?
|
| Artifacts | 1 | 2010 | 104 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2022 | 1243 | 0.080 |
Why?
|
| Factor XII | 1 | 2009 | 4 | 0.080 |
Why?
|
| Hemophilia B | 1 | 2009 | 7 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1584 | 0.080 |
Why?
|
| Polycythemia | 1 | 2009 | 42 | 0.080 |
Why?
|
| Middle Aged | 6 | 2024 | 26016 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 175 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 644 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2012 | 365 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2011 | 424 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 713 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 111 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2542 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2830 | 0.070 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 631 | 0.070 |
Why?
|
| Pathology | 1 | 2007 | 39 | 0.070 |
Why?
|
| Risk Factors | 5 | 2019 | 10015 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 360 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2012 | 649 | 0.070 |
Why?
|
| Sepsis | 1 | 2010 | 477 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 430 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 21 | 0.060 |
Why?
|
| Erythrocyte Indices | 1 | 2005 | 14 | 0.060 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 18 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 30 | 0.060 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 13 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 51 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2009 | 940 | 0.060 |
Why?
|
| Rodenticides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2014 | 4710 | 0.060 |
Why?
|
| Hematuria | 1 | 2004 | 53 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 73 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 180 | 0.060 |
Why?
|
| Factor VIIa | 1 | 2023 | 24 | 0.060 |
Why?
|
| Patient Care Team | 2 | 2019 | 548 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 55 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2006 | 204 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2024 | 211 | 0.050 |
Why?
|
| Animals | 4 | 2018 | 33759 | 0.050 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 779 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 223 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 413 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2013 | 120 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 4514 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 752 | 0.040 |
Why?
|
| Body Weight | 2 | 2017 | 1001 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 1874 | 0.040 |
Why?
|
| Inpatients | 1 | 2003 | 464 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 41 | 0.040 |
Why?
|
| Fibrin | 1 | 2020 | 67 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2226 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1388 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 156 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 53 | 0.040 |
Why?
|
| Placenta Previa | 1 | 2019 | 63 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3249 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 235 | 0.040 |
Why?
|
| Hemolysis | 1 | 2018 | 105 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2018 | 70 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2839 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 601 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2026 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 26 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 132 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 35 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 222 | 0.030 |
Why?
|
| Body Composition | 1 | 2019 | 513 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 635 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 437 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 537 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 1593 | 0.030 |
Why?
|
| Integrin alpha2 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Erythrocyte Aging | 1 | 2015 | 8 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2018 | 672 | 0.030 |
Why?
|
| Birth Weight | 1 | 2017 | 336 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 582 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1151 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 87 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 369 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 172 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 391 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 906 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 33 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 247 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 659 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 133 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 110 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 323 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 1138 | 0.030 |
Why?
|
| Software | 1 | 2017 | 678 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 313 | 0.030 |
Why?
|
| Medical Audit | 1 | 2012 | 100 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 557 | 0.020 |
Why?
|
| Glomerular Basement Membrane | 1 | 2011 | 9 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2011 | 19 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 542 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2011 | 73 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1093 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 190 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3560 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2012 | 195 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2011 | 172 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 483 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1726 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5049 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2011 | 233 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 1284 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 3 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 290 | 0.020 |
Why?
|
| Factor XI | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5773 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2007 | 13 | 0.020 |
Why?
|
| Quality Control | 1 | 2007 | 119 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1313 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 325 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19098 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 117 | 0.020 |
Why?
|
| Graft vs Host Reaction | 1 | 2005 | 9 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 1541 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2009 | 678 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 241 | 0.010 |
Why?
|
| United States | 2 | 2011 | 10637 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 174 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 3316 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2005 | 496 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 2406 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2058 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4353 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 17503 | 0.010 |
Why?
|